Literature DB >> 25628926

High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer.

Duan-Fang Shao1, Xiao-Hong Wang2, Zi-Yu Li1, Xiao-Fang Xing3, Xiao-Jing Cheng3, Ting Guo3, Hong Du3, Ying Hu2, Bin Dong4, Ning Ding1, Lin Li1, Shen Li1, Qing-Da Li1, Xian-Zi Wen3, Lian-Hai Zhang1, Jia-Fu Ji1.   

Abstract

BACKGROUND: The SUMO pathway has been shown to play an important role in tumorigenesis. This report analyzed the involvement of the sole SUMO-Activating Enzyme Subunit 2 (SAE2) in human gastric cancer (GC) progression and prognosis.
METHODS: Expression of SAE2 was examined by Quantigene Plex, western blotting and immunohistochemistry. The expression of SAE2 and c-MYC were detected in parallel in 276 cases. The molecular mechanisms of SAE2 expression and its effects on cell growth, colony formation, migration and invasion were also explored by CCK8 assay, colony formation experiment, transwell chamber assay with or without matrigel, immunoprecipitation and in vivo tumorigenesis and tumor metastasis.
RESULTS: SAE2 was markedly overexpressed in GC cell lines and primary tumor samples of GC, and significantly correlated with deeper tumor depth, distant metastasis, higher pathological stage and stratified survival in human GC. SAE2 positivity was independently associated with a worse outcome in multivariate analysis. Knockdown of SAE2 expression inhibited the proliferation, migration, and invasion of SAE2-overexpressing GC cells. Consistent with the in vitro results, down-regulation of SAE2 in human GC BGC823 cells significantly reduced the tumorigenic and metastatic potential of the cells in vivo. SAE2 protein was significantly associated with the higher expression of c-MYC in primary GC tissues. Moreover, FoxM1 was SUMOylated in GC and that inhibition of SAE2 resulted in a decrease in SUMO1-FoxM1 levels compared with those in the controls.
CONCLUSIONS: These findings suggest that SAE2 has a pivotal role in the aggressiveness of GC, and highlight its usefulness as a prognostic factor in GC.

Entities:  

Keywords:  FoxM1; SAE2; c-MYC; gastric cancer; prognosis

Year:  2014        PMID: 25628926      PMCID: PMC4300690     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  33 in total

1.  SUMO-activating SAE1 transcription is positively regulated by Myc.

Authors:  Stefano Amente; Miriam Lubrano Lavadera; Giacomo Di Palo; Barbara Majello
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

2.  Sumoylation by Ubc9 regulates the stem cell compartment and structure and function of the intestinal epithelium in mice.

Authors:  Maud D Demarque; Karim Nacerddine; Hélène Neyret-Kahn; Alexandra Andrieux; Esther Danenberg; Grégory Jouvion; Perrine Bomme; Ghislaine Hamard; Béatrice Romagnolo; Benoît Terris; Ana Cumano; Nick Barker; Hans Clevers; Anne Dejean
Journal:  Gastroenterology       Date:  2010-10-14       Impact factor: 22.682

Review 3.  SUMO and NF-kappaB ties.

Authors:  A M Mabb; S Miyamoto
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

4.  Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein.

Authors:  Joost Schimmel; Karolin Eifler; Jón Otti Sigurðsson; Sabine A G Cuijpers; Ivo A Hendriks; Matty Verlaan-de Vries; Christian D Kelstrup; Chiara Francavilla; René H Medema; Jesper V Olsen; Alfred C O Vertegaal
Journal:  Mol Cell       Date:  2014-02-27       Impact factor: 17.970

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.

Authors:  Tetsuya Ueda; Stefano Volinia; Hiroshi Okumura; Masayoshi Shimizu; Cristian Taccioli; Simona Rossi; Hansjuerg Alder; Chang-gong Liu; Naohide Oue; Wataru Yasui; Kazuhiro Yoshida; Hiroki Sasaki; Sachiyo Nomura; Yasuyuki Seto; Michio Kaminishi; George A Calin; Carlo M Croce
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

7.  A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Authors:  Jessica D Kessler; Kristopher T Kahle; Tingting Sun; Kristen L Meerbrey; Michael R Schlabach; Earlene M Schmitt; Samuel O Skinner; Qikai Xu; Mamie Z Li; Zachary C Hartman; Mitchell Rao; Peng Yu; Rocio Dominguez-Vidana; Anthony C Liang; Nicole L Solimini; Ronald J Bernardi; Bing Yu; Tiffany Hsu; Ido Golding; Ji Luo; C Kent Osborne; Chad J Creighton; Susan G Hilsenbeck; Rachel Schiff; Chad A Shaw; Stephen J Elledge; Thomas F Westbrook
Journal:  Science       Date:  2011-12-08       Impact factor: 47.728

Review 8.  A novel link between SUMO modification and cancer metastasis.

Authors:  Sung Hee Baek
Journal:  Cell Cycle       Date:  2006-07-17       Impact factor: 4.534

Review 9.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

10.  Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression.

Authors:  Qiang Li; Nu Zhang; Zhiliang Jia; Xiangdong Le; Bingbing Dai; Daoyan Wei; Suyun Huang; Dongfeng Tan; Keping Xie
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more
  10 in total

Review 1.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

Review 2.  Sumoylation in Physiology, Pathology and Therapy.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

3.  Ubiquitin-like modifier activating enzyme 2 promotes cell migration and invasion through Wnt/β-catenin signaling in gastric cancer.

Authors:  Ji Li; Xun Sun; Ping He; Wan-Qi Liu; Ya-Bin Zou; Quan Wang; Xiang-Wei Meng
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

Review 4.  SUMOylation in Glioblastoma: A Novel Therapeutic Target.

Authors:  Brandon M Fox; Andrew Janssen; Dagoberto Estevez-Ordonez; Florian Gessler; Nunzio Vicario; Gustavo Chagoya; Galal Elsayed; Houman Sotoudeh; William Stetler; Gregory K Friedman; Joshua D Bernstock
Journal:  Int J Mol Sci       Date:  2019-04-15       Impact factor: 5.923

5.  WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemia.

Authors:  Yunqi Zhu; Xiangmin Tong; Ying Wang; Xiaoya Lu
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

6.  Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer.

Authors:  Shen Li; Ziyu Li; Ting Guo; Xiao-Fang Xing; Xiaojing Cheng; Hong Du; Xian-Zi Wen; Jia-Fu Ji
Journal:  Oncotarget       Date:  2016-02-02

Review 7.  The post-translational modification, SUMOylation, and cancer (Review).

Authors:  Zhi-Jian Han; Yan-Hu Feng; Bao-Hong Gu; Yu-Min Li; Hao Chen
Journal:  Int J Oncol       Date:  2018-02-22       Impact factor: 5.650

8.  UBA2 promotes proliferation of colorectal cancer.

Authors:  Ping He; Xun Sun; Hong-Jing Cheng; Ya-Bin Zou; Quan Wang; Chang-Li Zhou; Wan-Qi Liu; Yue-Ming Hao; Xiang-Wei Meng
Journal:  Mol Med Rep       Date:  2018-10-30       Impact factor: 2.952

Review 9.  Developing Practical Therapeutic Strategies that Target Protein SUMOylation.

Authors:  Olivia F Cox; Paul W Huber
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

Review 10.  SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.

Authors:  Karolin Eifler; Alfred C O Vertegaal
Journal:  Trends Biochem Sci       Date:  2015-10-22       Impact factor: 13.807

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.